Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Don S.Boller who wrote (4287)	3/10/1998 5:50:00 AM
From: Rocketman	Respond to of 9719

Myotrophin Scheduled for April FDA Advisory Panel Meeting Monday March 9, 9:15 am Eastern Time biz.yahoo.com Here we go again! Think they can get it by the FDA this time? I think CEPH got bent over and had Uncle Sam show them his riding tricks, like the pole dance......and CEPH, it's shareholders and more so, the ALS sufferers were the ones getting the shaft. Well, it's grudge time again at the FDA. Has Congress rescued CEPH, will the evil advisory panel by one vote deny treatment to thousands of people who want it and have no other good options. CEPH is either a $4 stock or a $25 stock and it will be a hell of a roller coaster ride one way or the other. To Chiron, I don't think it matters much in reality, although good news here would help salvage their reputation some and maybe move their stock out of the doldrums. Rman